Literature DB >> 8192464

Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.

B E Gilbert1, P R Wyde, G Lopez-Berestein, S Z Wilson.   

Abstract

Mice lethally infected with Candida albicans were exposed to small-particle aerosols containing amphotericin B-liposomes. The drug, when administered twice daily for 2 h (0.58 mg/kg of body weight per day) on days 1, 2, and 3 postinoculation, significantly reduced the numbers of Candida organisms in the kidneys. Aerosol treatment increased the survival time of mice given 2 2-h treatments once a week for 4 weeks. A twice-weekly, 2-h small-particle aerosol administration of amphotericin B-liposomes for 1, 2, or 3 weeks significantly increased both the mean time of survival and percent survival.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192464      PMCID: PMC284455          DOI: 10.1128/AAC.38.2.356

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

3.  Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Authors:  J M Clark; R R Whitney; S J Olsen; R J George; M R Swerdel; L Kunselman; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

5.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol.

Authors:  P R Wyde; S Z Wilson; B E Gilbert; R H Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 7.  The growing problem of mycoses in patients infected with the human immunodeficiency virus.

Authors:  R D Diamond
Journal:  Rev Infect Dis       Date:  1991 May-Jun

8.  Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.

Authors:  B E Gilbert; P R Wyde; S Z Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; E M Bernard; M Häuser; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

10.  Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  J A Gondal; R P Swartz; A Rahman
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more
  2 in total

Review 1.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 2.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.